Susumu Hijioka, MD, on the Phase III STARTER-NET Study in GEP-NET
Susumu Hijioka, MD, of the National Cancer Center, Tokyo, discusses results from the phase III JCOG1901 STARTER-NET study in patients with gastroenteropancreatic neuroendocrine (GEP-NET) tumors. The study evaluated combination therapy with everolimus plus lanreotide vs everolimus monotherapy for unresectable or recurrent GEP-NETs (Abstract 652).